BiotechTube

PF-08634404 + Enfortumab Vedotin

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urothelial Cancer

Conditions

Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma

Trial Timeline

Feb 27, 2026 → Sep 5, 2028

NCT ID
NCT07421700

About PF-08634404 + Enfortumab Vedotin

PF-08634404 + Enfortumab Vedotin is a phase 1/2 stage product being developed by Astellas Pharma for Urothelial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07421700. Target conditions include Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07421700Phase 1/2Recruiting

Competing Products

20 competing products in Urothelial Cancer

See all competitors
ProductCompanyStageHype Score
Dato-DXd + Carboplatin + Cisplatin + GemcitabineDaiichi SankyoPhase 2/3
65
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab vedotin + Pembrolizumab + Cisplatin + Carboplatin + GemcitabineAstellas PharmaPhase 3
77
Enfortumab vedotinAstellas PharmaPhase 1
33
AGS15EAstellas PharmaPhase 1
33
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
Enfortumab VedotinAstellas PharmaPhase 2
52
Enfortumab VedotinAstellas PharmaApproved
85
Enfortumab vedotinAstellas PharmaPhase 2
52
Enfortumab VedotinAstellas PharmaPre-clinical
23
enfortumab vedotinAstellas PharmaPhase 1
33
Eribulin Mesylate + AvelumabEisaiPhase 1
33
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77
KHK2455 + AvelumabKyowa KirinPhase 1
33
Nivolumab 100 MG in 10 ML InjectionOno PharmaceuticalPhase 2
52
Nivolumab + Ipilimumab + Gemcitabine + Cisplatin + CarboplatinOno PharmaceuticalPhase 3
77
Ramucirumab + Docetaxel + PlaceboEli LillyPhase 3
77
Livmoniplimab + Budigalimab + Docetaxel + Paclitaxel + Docetaxel + Paclitaxel + GemcitabineAbbViePhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85